Esperion Therapeutics Inc., of Plymouth, Mich., reported top-line results from a Phase IIa trial of ETC-1002 for hypercholesterolemia in patients with a history of intolerance to two or more statins
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., and Bayer HealthCare Pharmaceuticals Inc., of Wayne, N.J., disclosed positive top-line results for Eylea (aflibercept) Injection from the Phase III MYRROR study in myopic choroidal neovascularization
Euthymics Bioscience Inc., of Cambridge, Mass., reported top-line results from TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects), a Phase IIb/IIIa study designed to assess the safety and efficacy of amitifadine, a serotonin-preferring triple reuptake inhibitor antidepressant, in patients with major depressive disorder (MDD) failing to respond to one course of first-line antidepressants
Novo Nordisk A/S, of Bagsvaerd, Denmark, reported top-line results from a 56-week Phase IIIa trial testing the potential of GLP-1 drug liraglutide to induce and maintain weight loss in people without diabetes who are obese or overweight with co-morbidities such as prediabetes, hypertension and dyslipidemia
Acelrx Pharmaceuticals Inc., of Redwood City, Calif., reported top-line data that showed its sublingual Sufentanil NanoTab PCA (patient-controlled analgesia) System met the primary and secondary efficacy endpoints in a placebo-controlled, Phase III study
The confirmatory trial is identical in design to the company's previous Phase III study, which reported positive top-line findings in March...The company expects to report top-line results from the current study in late 2013 or early 2014 and to file a new drug application with the FDA in 2014. (See BioWorld Today, March 20, 2013
These data led to Eleven's Phase Ib clinical study of EBI-005 in subjects with dry eye disease, with top-line data from the Phase Ib study expected in the second half of 2013
Pfizer Inc., of New York, said that top-line data for a Phase IV trial of Celebrex (celecoxib) capsules or naproxen in juvenile idiopathic arthritis patients demonstrated no difference in changes to systolic blood pressure, the primary endpoint, and diastolic blood pressure, the secondary endpoint
Ceregene Inc., of San Diego, reported top-line data from its double-blind, randomized, controlled Phase IIb study of CERE-120 (AAV-neurturin), a gene therapy designed to deliver the neurotrophic factor neurturin, for Parkinson's disease...Civitas Therapeutics Inc., of Chelsea, Mass., disclosed positive top-line results from a Phase II trial of CVT-301, an inhaled formulation of levodopa (L-dopa
Concert expects to report top-line results by the end of 2013